ALEXANDRIA, Va., Oct. 8 -- United States Patent no. 12,435,101, issued on Oct. 7, was assigned to Zhejiang Yangli Pharmaceutical Technology Co. Ltd. (Zhejiang, China).
"Isochroman compound" was invented by Zhe Cai (Shanghai), Fei Sun (Shanghai), Charles Z. Ding (Shanghai) and Shuhui Chen (Shanghai).
According to the abstract* released by the U.S. Patent & Trademark Office: "Provided is an isochroman compound represented by formula (I), or a pharmaceutically acceptable salt thereof, which is used as an aldo-keto reductase (AKR1C3) inhibitor for the treatment of liver cancer."
The patent was filed on Sept. 15, 2021, under Application No. 18/044,791.
*For further information, including images, charts and tables, please visit: http://patft....